<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.109302</article-id><article-id pub-id-type="publisher-id">ACM-37691</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200900000_78910662.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  D-二聚体在恶性肿瘤中应用价值的研究进展
  Research Progress on the Application Value of D-Dimer in Malignant Tumors
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>董</surname><given-names>玉倩</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>null</addr-line></aff><aff id="aff2"><label>1</label><addr-line>延安大学附属医院肿瘤科一病区，陕西 延安</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>09</month><year>2020</year></pub-date><volume>10</volume><issue>09</issue><fpage>2017</fpage><lpage>2023</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    D-二聚体作为纤维蛋白降解产物，在静脉血栓中具有重要的排除价值。D-二聚体的形成与凝血酶、纤维蛋白溶酶活化密切相关，其浓度水平受多种因素调控。既往研究证实，肿瘤与患者高凝状态关系密切，并指出约50%的恶性肿瘤患者及超过90%的转移患者存在凝血功能异常及血栓形成现象。癌细胞可直接促进凝血系统激活，进而产生凝血酶或间接通过刺激单核细胞合成多种促凝因子。近年来，国内外关于D-二聚体的基础研究、临床研究以及流行病学研究大量涌现，尤其在各类恶性肿瘤如非小细胞肺癌、胃腺癌、胰腺癌、原发性肝癌的早期预测和晚期预后评估中扮演重要角色。然而国内D-二聚体在各恶性肿瘤中的研究综述报道尚少，本文就D-二聚体在临床工作各系统常见的恶性肿瘤中的研究进展做一综述。
    D-dimer, as a fibrin degradation product, has important elimination values in venous thrombosis. The formation of D-dimer is closely related to the activation of thrombin and plasmin, and its concentration level is regulated by many factors. Previous studies have confirmed that tumors are closely related to the hypercoagulable state of patients, and pointed out that about 50% of patients with malignant tumors and more than 90% of patients with metastases have abnormal blood coagulation and thrombosis. Cancer cells can directly promote the activation of the coagulation system, and then produce thrombin or indirectly stimulate monocytes to synthesize a variety of procoagulant factors. In recent years, a large number of basic research, clinical research and epidemiological research on D-dimer have emerged at home and abroad, especially in the early prediction of various malignant tumors such as non-small cell lung cancer, gastric adenocarcinoma, pancreatic cancer, and primary liver cancer. And late prognosis assessment plays an important role. However, domestic research reports on D-dimer in various malignant tumors are still few. This article reviews the research progress of D-dimer in common malignant tumors in various systems in clinical work. 
  
 
</p></abstract><kwd-group><kwd>D-二聚体，凝血，恶性肿瘤, D-Dimer</kwd><kwd> Blood Clotting</kwd><kwd> Malignant Tumor</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>D-二聚体作为纤维蛋白降解产物，在静脉血栓中具有重要的排除价值。D-二聚体的形成与凝血酶、纤维蛋白溶酶活化密切相关，其浓度水平受多种因素调控。既往研究证实，肿瘤与患者高凝状态关系密切，并指出约50%的恶性肿瘤患者及超过90%的转移患者存在凝血功能异常及血栓形成现象。癌细胞可直接促进凝血系统激活，进而产生凝血酶或间接通过刺激单核细胞合成多种促凝因子。近年来，国内外关于D-二聚体的基础研究、临床研究以及流行病学研究大量涌现，尤其在各类恶性肿瘤如非小细胞肺癌、胃腺癌、胰腺癌、原发性肝癌的早期预测和晚期预后评估中扮演重要角色。然而国内D-二聚体在各恶性肿瘤中的研究综述报道尚少，本文就D-二聚体在临床工作各系统常见的恶性肿瘤中的研究进展做一综述。</p></sec><sec id="s2"><title>关键词</title><p>D-二聚体，凝血，恶性肿瘤</p></sec><sec id="s3"><title>Research Progress on the Application Value of D-Dimer in Malignant Tumors</title><p>Yuqian Dong</p><p>First Ward of Oncology Department, Affiliated Hospital of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/22-1571560x4_hanspub.png" /></p><p>Received: Aug. 27<sup>th</sup>, 2020; accepted: Sep. 11<sup>th</sup>, 2020; published: Sep. 18<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/22-1571560x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>D-dimer, as a fibrin degradation product, has important elimination values in venous thrombosis. The formation of D-dimer is closely related to the activation of thrombin and plasmin, and its concentration level is regulated by many factors. Previous studies have confirmed that tumors are closely related to the hypercoagulable state of patients, and pointed out that about 50% of patients with malignant tumors and more than 90% of patients with metastases have abnormal blood coagulation and thrombosis. Cancer cells can directly promote the activation of the coagulation system, and then produce thrombin or indirectly stimulate monocytes to synthesize a variety of procoagulant factors. In recent years, a large number of basic research, clinical research and epidemiological research on D-dimer have emerged at home and abroad, especially in the early prediction of various malignant tumors such as non-small cell lung cancer, gastric adenocarcinoma, pancreatic cancer, and primary liver cancer. And late prognosis assessment plays an important role. However, domestic research reports on D-dimer in various malignant tumors are still few. This article reviews the research progress of D-dimer in common malignant tumors in various systems in clinical work.</p><p>Keywords:D-Dimer, Blood Clotting, Malignant Tumor</p><disp-formula id="hanspub.37691-formula10"><graphic xlink:href="//html.hanspub.org/file/22-1571560x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/22-1571560x7_hanspub.png" /> <img src="//html.hanspub.org/file/22-1571560x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>血管壁损伤、血液成份异常等激活体内凝血系统导致血栓形成，继而纤维蛋白溶解(纤溶)系统激活，纤维蛋白降解形成D-二聚体。血液高凝可能是促进肿瘤新生血管生成进一步加速其复发和远处转移的重要因素之一，这一过程需要非常复杂的途径参与，同时恶性肿瘤本身也会破坏机体的凝血系统以及抗凝血系统的平衡，从而会形成恶性的循环，加速肿瘤的进程，血栓形成的机率也大幅增加。D-二聚体可反映体内高凝状态和继发性纤溶亢进，近年来，多项研究表明D-二聚体在各类恶性肿瘤的发病、不良事件预测中具有重要价值。</p></sec><sec id="s6"><title>2. D-二聚体与乳腺癌</title><p>乳腺癌是女性最常见的恶性肿瘤，发病率呈逐年上升趋势，发病人群也越来越年轻化，严重危害了女性的生命健康及生活质量。恶性肿瘤患者普遍存在血液高凝状态，乳腺癌也不例外。</p><p>研究发现 [<xref ref-type="bibr" rid="hanspub.37691-ref1">1</xref>]：D-二聚体水平与淋巴结受累程度和浸润程度直接相关，D-二聚体水平与阳性淋巴结数目最相关，但与肿瘤大小、雌激素受体状态和孕激素受体状态无关。一项国外前瞻性研究 [<xref ref-type="bibr" rid="hanspub.37691-ref2">2</xref>] D-二聚体水平升高与晚期乳腺癌之间的关系，结果表明：晚期乳腺癌组中D-二聚体水平升高，且与肿瘤大小、分期、分级、淋巴管浸润和淋巴结受累有关。研究 [<xref ref-type="bibr" rid="hanspub.37691-ref3">3</xref>] D-二聚体在预测乳腺癌患者的深静脉血栓(DVT)形成方面的表现：术前D-二聚体可提高术后DVT风险的预测能力，D-二聚体是DVT事件的独立预测因子。</p><p>探讨检测乳腺癌患者D-二聚体水平对预防血栓形成的价值，也可以指导临床手术合理开展，促进患者康复，对临床手术预后及术后恶性血管事件发生有一定的指导意义。祁华良 [<xref ref-type="bibr" rid="hanspub.37691-ref4">4</xref>] 研究发现，乳腺癌患者D-二聚体水平较良性肿瘤高，且术后7天高于术前，术后30天、2个月时血浆D-二聚体水平明显低于术前和术后1周。而良性肿瘤患者术后高于术前，尽管手术造成损伤致患者血浆D-二聚体水平升高，但患者本身未出现明显凝血功能失衡现象。根据此研究结果我认为：血浆D-二聚体水平可较好地反映人体体内高凝状态，通过检测血浆D-二聚体水平来判断患者高凝与纤溶状况，有效预测血栓形成风险程度，对指导乳腺癌术后合理抗凝治疗具有重要价值，有利于避免血栓形成，促进患者康复。乳腺癌患者存在一定程度凝血功能紊乱，且手术治疗具有一定创伤性，为有效预防血栓形成，术前、术后及时监测血浆D-二聚体水平以指导临床医师合理抗凝治疗。</p><p>关于乳腺癌患者血浆纤维蛋白原(Fibrinogen FIB)、D-二聚体和抗凝血酶III (AT-III)活性水平的变化及与临床分期的关系，川北医学院附属医院的一项临床研究 [<xref ref-type="bibr" rid="hanspub.37691-ref5">5</xref>] 得出结论：乳腺癌患者临床TNM分期越高，血浆FIB、D-二聚体水平越高，AT-III活性越低。乳腺癌患者T分期越高，血浆FIB水平越高，不同T分期患者FIB水平比较，差异均有统计学意义(均P &lt; 0.05)，D-二聚体和AT-III活性比较差异均无统计学意义(均P &gt; 0.05)。乳腺癌患者N分期越高，血浆FIB水平越高，差异均有统计学意义(均P &lt; 0.05)。不同N分期乳腺癌患者血浆D-二聚体、AT-III活性水平比较差异均无统计学意义(均P &gt; 0. 05)。根据此研究结果我认为：乳腺癌患者TNM分期越高，血浆FIB、D-二聚体水平越高，AT-Ⅲ活性越低，监测乳腺癌患者血浆FIB、D-二聚体和AT-III活性有助于对患者病情与预后的评估，同时，有助于临床得出关于测定凝血对于乳腺癌TNM分期的间接指导意义。</p><p>综上，笔者认为：D-二聚体水平与乳腺癌患者淋巴结受累情况直接相关，同时，对于乳腺癌的乳腺癌患者静脉不良事件发生情况也有一定的指导监测意义。在整个治疗过程中乳腺癌患者易出现血液高凝，且术后更明显，相较于其他凝血指标，FIB、D-D变化显著。对乳腺癌患者进行凝血功能指标的检测可为患者制定针对性治疗方案及判断预后提供一定的参考，但凝血指标不能完全作为诊断肿瘤及判断预后的直接性指标，临床中应结合临床、病理因素进行综合分析。</p></sec><sec id="s7"><title>3. D-二聚体与泌尿系统肿瘤</title><p>一项前瞻性观察队列研究 [<xref ref-type="bibr" rid="hanspub.37691-ref6">6</xref>] 调查了1269例泌尿外科肿瘤手术的患者术后D-二聚体以预测肺栓塞(PE)和深静脉血栓栓塞(DVT)的发生率，结论：泌尿外科肿瘤的整体发生率亚洲人群中与手术相关的VTE与欧洲和北美的系列报道相似。泌尿外科术后早期D-二聚体升高是泌尿外科肿瘤手术患者发生VTE的独立预测指标，术后D-二聚体水平是确定处于发展中的静脉高危患者的更可靠指标。研究 [<xref ref-type="bibr" rid="hanspub.37691-ref7">7</xref>] 分析在泌尿系统恶性肿瘤手术前D-二聚体生高的患者深静脉血栓形成DVT的发生率和预测指标：多变量分析显示泌尿系统恶性肿瘤的主要部位(P &lt; 0.01)和老年(P &lt; 0.01)是DVT的独立预测因子。膀胱癌患者的DVT发生率最高。结论：DVT在泌尿系统恶性肿瘤手术前18%的D-二聚体升高的患者中被发现，膀胱癌患者和D-二聚体升高的老年患者应接受DVT的早期检查。</p><p>一项回顾性研究 [<xref ref-type="bibr" rid="hanspub.37691-ref8">8</xref>] 评估术前D-二聚体作为生物标志物的能力以预测非浸润性膀胱癌患者的生存结局：Kaplan-Meier分析表明高D-二聚体水平与不良无复发生存率(RFS)和无进展生存期(PFS)显著相关，与晚期病理分期、肿瘤大学和多个肿瘤病变有显著相关性。表明术前D-二聚体水平升高可能表示临床病理特征恶化和预后不良。回顾性研究 [<xref ref-type="bibr" rid="hanspub.37691-ref9">9</xref>] 术前血浆D-二聚体水平作为根治性肾切除后上尿路上皮癌患者预后指标的价值，结果为：血浆D-二聚体水平 ≥ 0.36 mg/L与晚期肿瘤状态显著相关，包括大小、位置、肾积水、肿瘤分级、淋巴结受累、等级和分期(所有p &lt; 0.001)。单因素与多因素分析显示，术前D-二聚体水平升高是无复发生存率的独立预测因子。</p><p>综上，笔者认为：术后D-二聚体升高是泌尿外科肿瘤手术相关的深静脉栓塞发生的独立预测指标，因此，在临床工作中，D-二聚体升高的泌尿系统恶性肿瘤患者应接受动态深静脉多普勒超声的早期检查，同时预防性使用抗凝药物，防止术后DVT的发生。</p></sec><sec id="s8"><title>4. D-二聚体与妇科肿瘤</title><p>一项回顾性分析 [<xref ref-type="bibr" rid="hanspub.37691-ref10">10</xref>] 血浆D-二聚体水平在上皮性卵巢癌(EOC)中的预后意义得出结论：EOC患者的治疗前D-二聚体水平升高与预后不良相关，而与VTE无关。而另一项回顾性分析 [<xref ref-type="bibr" rid="hanspub.37691-ref11">11</xref>] 围手术期上皮性卵巢癌(EOC)患者静脉血栓栓塞(VTE)的发生率和危险因素的研究则表明：对于预测VTE发生：术前D-二聚体水平(&gt;4.215 ug/ml)是独立的预测因子，对于EOC患者必须进行更有效的血栓预防和预测试评估。笔者认为：对于EOC术前D-二聚体水平升高与VTE发生是否相关，业内的一些研究存在争议，这需要我们继续研究，早日得出权威证据指导临床工作。</p><p>一项纳入942例接受手术的子宫内膜癌患者的研究 [<xref ref-type="bibr" rid="hanspub.37691-ref12">12</xref>]，确定在手术治疗的子宫内膜癌中具有预后价值的凝血标志物，得到结论：纤维蛋白原水平是子宫内膜癌的重要独立预后因素，PT、APTT、TT、PTA和D－二聚体水平不能作为子宫内膜癌的独立预后因素。静脉血栓栓塞症(VTE)是妇科恶性肿瘤术后患者发病和死亡的主要原因。</p><p>一项验证升高的D-二聚体作为妇科恶性肿瘤手术患者术后VTE的预测指标的研究 [<xref ref-type="bibr" rid="hanspub.37691-ref13">13</xref>]，得到结果：如果将1.5 ug/ml用作VTE的D-二聚体临界值，则灵敏度为87.5%，特异性为93.8%，阴性预测值为99.2%。D-二聚体水平是延长围手术期抗凝剂使用的标志。结论：大于1.5 ug/ml的D-二聚体在手术前应引起可能发生VTE的注意。</p><p>宫颈癌(CC)是全球女性的第四大恶性肿瘤，转移是大多数CC患者治疗失败的主要原因，细胞粘附因1(CADM1)启动子甲基化和血浆D-二聚体的结合测定是预测转移的两个参数 [<xref ref-type="bibr" rid="hanspub.37691-ref14">14</xref>]，具有较高的敏感性(80.4%)和特异性(90.5%)。</p><p>卵巢癌是妇科肿瘤患者中致死的首要因素，研究结果显示 [<xref ref-type="bibr" rid="hanspub.37691-ref15">15</xref>]，卵巢癌组患者血浆D-二聚体和纤溶酶原激活物抑制剂1(PAI-1)水平均显著高于卵巢良性肿瘤组及对照组；但卵巢良性肿瘤组患者血浆D-二聚体和PAI-1水平并未发生显著上调。进一步对不同分期卵巢癌患者血浆D-二聚体和PAI-1水平分析发现，D-二聚体和PAI-1水平在卵巢癌患者中随着肿瘤进展呈不断上升趋势。提示D-二聚体和PAI-1水平与卵巢癌分期密切相关，高水平D-二聚体和PAI-1患者具有转移的倾向及术后较差结果的可能，这也为临床决定手术患者选择提供了辅助参考。</p><p>综上，笔者认为：对于妇科恶性肿瘤D-二聚体水平与VTE的发生存在一定争议，这需要科研工作者及临床医师共同努力，早日得出更权威证据指导临床工作。但是，对于术前D-二聚体异常升高的患者应该引起可能发生VTE的注意。D-二聚体也可与其他凝血系列指标联合测定提示肿瘤的发生、发展及预后。</p></sec><sec id="s9"><title>5. D-二聚体与非小细胞肺癌</title><p>肺癌患者的VTE发生率较高。一项目的为调查与术后VTE相关的危险因素并探讨D-二聚体动力学的VTE预测能力的回顾性研究 [<xref ref-type="bibr" rid="hanspub.37691-ref16">16</xref>]，结果如下：年龄 &gt; 60岁和术后D-二聚体水平是VTE的独立危险因素，结论：肺肿瘤手术后连续检测D-二聚体水平并结合血栓相关危险因素可以更好地评估VTE的发生。一项旨在确定围手术期D-二聚体的早期预测和风险分层的临界值是否会改善VTE的诊断效力的病例对照研究 [<xref ref-type="bibr" rid="hanspub.37691-ref17">17</xref>] 得出结论：非小细胞肺癌患者术后D-二聚体水平升高，手术选择和肿瘤分期对D-二聚体水平有影响。根据手术方法和疾病阶段调整风险分层的D-二聚体将有助于预测术后VTE的发生。同时，我们发现 [<xref ref-type="bibr" rid="hanspub.37691-ref9">9</xref>] 血浆纤维蛋白原和D-二聚体的术前联合检测对于确定手术切除的非小细胞肺癌患者很有必要，比单独使用具有更好的预后价值。</p><p>一项纳入362例接受根治性手术的非小细胞癌患者的回顾性研究 [<xref ref-type="bibr" rid="hanspub.37691-ref18">18</xref>] 表示：在CT表现为实体瘤的非小细胞肺癌患者中，D-二聚体水平高，无明显生存差异。而有的学者则经过综合荟萃分析后认为：较高的D-二聚体水平仍然是非小细胞肺癌术后不良预后的独立预测因子 [<xref ref-type="bibr" rid="hanspub.37691-ref19">19</xref>]。血小板(PLT)、纤维蛋白原(FIB)和D-二聚体水平对于非小细胞肺癌预后的综合影响有待研究，一项在七家医院进行的多中心前瞻性研究 [<xref ref-type="bibr" rid="hanspub.37691-ref20">20</xref>] 得出结论：多水平分析显示，PLT水平升高与无进展生存期(PFS)之间存在显著关联，而术前FIB和D-二聚体并不是PFS的重要预后因素。与三种凝血因子中一种升高的患者相比，三种因子中至少两种升高的患者具有更高的癌症进展风险，并可用于预测非小细胞肺癌术后的患者预后情况。但三种凝血因子之间的相互作用值得进一步研究。</p><p>我们发现D-二聚体可对于高度怀疑为肺肿瘤的肺小结节患者的诊断提供一定意义。研究发现 [<xref ref-type="bibr" rid="hanspub.37691-ref21">21</xref>]：非小细胞肺癌患者的D-二聚体在统计学上高于肺良性结节患者，D-二聚体升高与恶性淋巴结受累数量与肿瘤大小之间存在明显证据。血浆D-二聚体可能有助于非小细胞癌患者的早期诊断、分期和预后。</p><p>王佳丽 [<xref ref-type="bibr" rid="hanspub.37691-ref22">22</xref>] 在一项探究在探究140例非小细胞肺癌患者参加的临床实验中探究D-二聚体水平对预后的影响，并分析D-二聚体在肺癌肺栓塞与非肺栓塞患者之间的差异，并得出结论：析单因素分析结果显示，年龄不影响患者生存。而性别、吸烟史、病理类型、病理学状态、肿瘤大小、PS评分、是否接受一线化疗和D-二聚体与肺癌预后有关。Cox多因素结果显示病理学状态、肿瘤大小和D-二聚体是影响本组患者的独立预后因素。D-二聚体水平对肺栓塞发生影响本组140患者中根据临床症状和检查结果，有19例患者出现肺栓塞；且经CT证实，肺栓塞患者D-二聚体值为(5.37 &#177; 1.23) μg/mL，而非肺栓塞患者(0.43 &#177; 0.73) μg/mL，两者比较差异有统计学意义(P &lt; 0.05)。</p><p>综上，笔者认为：D-二聚体与血浆纤维蛋白原和D-二聚体的术前联合检测对于确定手术切除的非小细胞肺癌患者很有必要，可以预测VTE的发生，比单独使用具有更好的预后价值。同时，对于凝血因子测定指导非小细胞肺癌的进展，更建议多种凝血因子综合分析，三种因子中至少两种升高的患者具有更高的癌症进展风险，并可用于预测非小细胞肺癌术后的患者预后情况。但三种凝血因子之间的相互作用值得进一步研究。D-二聚体水平测定对于非小细胞肺癌与肺部良性结节的鉴别、非小细胞肺癌早期诊断、分期、进展、手术指导、预后及肺栓塞的发生均有重大临床指导意义。</p></sec><sec id="s10"><title>6. D-二聚体与结直肠癌</title><p>静脉血栓栓塞症(VTE)是结肠癌的常见并发症。术前血浆纤维蛋白原(FIB)和D-二聚体水平均与淋巴结转移情况相关，而且术前血浆FIB和D-二聚体水平越高，患者生存率越低 [<xref ref-type="bibr" rid="hanspub.37691-ref23">23</xref>]。二者有望成为预测结直肠癌是否淋巴结转移及预后的肿瘤标志物。术前D-二聚体和血清癌胚抗原(CEA)水平可用于预测结直肠癌的分期和分化程度 [<xref ref-type="bibr" rid="hanspub.37691-ref24">24</xref>]。CEA水平的变化可以作为化疗反应的预测生物标记物，而基线D-二聚体水平可以作为患者总生存期(OS)预后的生物标记物 [<xref ref-type="bibr" rid="hanspub.37691-ref25">25</xref>]。术前CEA和D-二聚体水平可预测结直肠癌病理分期，术后CEA和D-二聚体水平可监测结直肠癌复发转移，并与术后生存率呈负相关关系 [<xref ref-type="bibr" rid="hanspub.37691-ref26">26</xref>]。一项前瞻性队列研究验证三种凝血参数：纤维蛋白原，纤维蛋白降解产物(FDPs)和D-二聚体在非转移性结直肠癌中的预后意义，得出结论： [<xref ref-type="bibr" rid="hanspub.37691-ref27">27</xref>] 术前纤维蛋白原水平是非转移性结直肠癌患者的独立死亡危险因素。</p></sec><sec id="s11"><title>7. 总结与展望</title><p>一直以来，D-二聚体一直被用来排除静脉血栓栓塞症。然而，近年来多项临床及流行病学对D-二聚体的研究，深入提高了D-二聚体的阴性预测价值，同时纵向拓展了D-二聚体在恶性肿瘤中的新应用，包括对于临床各种常见恶性肿瘤的诊断、分期、进展和预后息息相关，并有可能成为指导抗凝治疗策略的新指标。然而，D-二聚体是纤维蛋白降解产物，其浓度受多系统调节，且与年龄等诸多危险因素相关，目前关于D-二聚体与恶性肿瘤患者VTE发病率，高龄患者静脉血栓排除等相关临床研究尚存有争议，此外，许多研究人群规模较小，因此，未来还需要更多大规模以及多中心的研究来证实；以及对入选人群的特征等其他相关指标进行综合、深入分析研究。</p></sec><sec id="s12"><title>文章引用</title><p>董玉倩. D-二聚体在恶性肿瘤中应用价值的研究进展Research Progress on the Application Value of D-Dimer in Malignant Tumors[J]. 临床医学进展, 2020, 10(09): 2017-2023. https://doi.org/10.12677/ACM.2020.109302</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37691-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Harish, S., Raxith Sringeri, R. and Sarath Chandra, P. (2018) Role of Plasma D-Dimer Levels in Breast Cancer Patients and Its Correlation with Clinical and Histopathological Stage. Indian Journal of Surgical Oncology, 9, 307-311. 
&lt;br&gt;https://doi.org/10.1007/s13193-017-0682-x</mixed-citation></ref><ref id="hanspub.37691-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ghadhban, B.R. (2018) Plasma D-Dimer Level Correlated with Advanced Breast Carcinoma in Female Patients. Annals of Medicine and Surgery, 36, 75-78. &lt;br&gt;https://doi.org/10.1016/j.amsu.2018.10.025</mixed-citation></ref><ref id="hanspub.37691-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Cui, L.-N., Li, N., Fu, S., Zhang, X., Wang, X. and Wang, R.-T. (2018) Combination of Preoperative D-Dimer and Mean Platelet Volume Predicts Postoperative Deep Venous Thrombosis in Breast Cancer Patients. Cancer Biomarkers: Section a of Disease Markers, 21, 909-913. &lt;br&gt;https://doi.org/10.3233/CBM-170975</mixed-citation></ref><ref id="hanspub.37691-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">祁华良, 王海龙. 乳腺癌患者D-二聚体水平对预防血栓形成及对手术的指导意义[J]. 浙江创伤外科, 2020, 25(2): 313-314.</mixed-citation></ref><ref id="hanspub.37691-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">梁骑, 李君安, 邓健康, 等. 乳腺癌患者血浆纤维蛋白原和D-二聚体及抗凝血酶Ⅲ活性水平的变化及临床意义[J]. 中国医药, 2020, 15(6): 890-893.</mixed-citation></ref><ref id="hanspub.37691-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Shi, A., et al. (2018) Postoperative D-Dimer Predicts Venous Thromboembolism in Patients Undergoing Urologic Tumor Surgery. Urologic Oncology, 36, 307.e15-307.e21. &lt;br&gt;https://doi.org/10.1016/j.urolonc.2018.03.003</mixed-citation></ref><ref id="hanspub.37691-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Fujiwara, R., et al. (2020) Incidence and Predictors of Deep Vein Thrombosis in Patients with Elevated Serum D-Dimer Prior to Surgery for Urologic Malignancy. Urologia Internationalis, 104, 16-21. 
&lt;br&gt;https://doi.org/10.1159/000502660</mixed-citation></ref><ref id="hanspub.37691-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., et al. (2020) Preoperative Plasma Fibrinogen and D-Dimer as Prognostic Biomarkers for Non-Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 18, 11-19. &lt;br&gt;https://doi.org/10.1016/j.clgc.2019.10.025</mixed-citation></ref><ref id="hanspub.37691-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X., et al. (2020) Prognostic Value of the Preoperative Plasma D-Dimer Levels in Patients with Upper Tract Urothelial Carcinoma in a Retrospective Cohort Study. Oncotargets and Therapy, 13, 5047-5055. 
&lt;br&gt;https://doi.org/10.2147/OTT.S254514</mixed-citation></ref><ref id="hanspub.37691-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Yamada, Y., et al. (2020) Preoperative Plasma D-Dimer Level Is a Useful Prognostic Marker in Ovarian Cancer. Journal of Obstetrics and Gynaecology, 40, 102-106. &lt;br&gt;https://doi.org/10.1080/01443615.2019.1606176</mixed-citation></ref><ref id="hanspub.37691-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Q.Q., et al. (2020) Incidence and Potential Predictors of Thromboembolic Events in Epithelial Ovarian Carcinoma Patients during Perioperative Period. European Journal of Surgical Oncology, 46, 855-861. 
&lt;br&gt;https://doi.org/10.1016/j.ejso.2020.01.026</mixed-citation></ref><ref id="hanspub.37691-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Shiina, Y., et al. (2019) The D-Dimer Level Predicts the Postoperative Prognosis in Patients with Non-Small Cell Lung Cancer. PLoS ONE, 14, e0222050. &lt;br&gt;https://doi.org/10.1371/journal.pone.0222050</mixed-citation></ref><ref id="hanspub.37691-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Shi, J., Ye, J., Zhuang, X., Cheng, X.Y., Fu, R.J. and Zhao, A. (2019) Application Value of Caprini Risk Assessment Model and Elevated Tumor-Specific D-Dimer Level in Predicting Postoperative Venous Thromboembolism for Patients Undergoing Surgery of Gynecologic Malignancies. The Journal of Obstetrics and Gynaecology Research, 45, 657-664. &lt;br&gt;https://doi.org/10.1111/jog.13832</mixed-citation></ref><ref id="hanspub.37691-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Rong, G.D., Zhang, M.J., Xia, W.Y., Li, D.H., Miao, J. and Wang, H. (2019) Plasma CADM1 Promoter Hypermethylation and D-Dimer as Novel Metastasis Predictors of Cervical Cancer. The Journal of Obstetrics and Gynaecology Research, 45, 1251-1259. &lt;br&gt;https://doi.org/10.1111/jog.13966</mixed-citation></ref><ref id="hanspub.37691-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">赵丹丹. 血浆D-二聚体及PAI-1水平在卵巢癌患者中的变化及临床意义[J]. 现代医药卫生, 2020, 36(2): 247-249.</mixed-citation></ref><ref id="hanspub.37691-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wang, P., et al. (2020) Risk Factors and Clinical Significance of D-Dimer in the Development of Postoperative Venous Thrombosis in Patients with Lung Tumor. Cancer Management and Research, 12, 5169-5179. 
&lt;br&gt;https://doi.org/10.2147/CMAR.S256484</mixed-citation></ref><ref id="hanspub.37691-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Ke, L.H., Cui, S.P., Chen, S. and Hu, B. (2020) Dynamics of D-Dimer in Non-Small Cell Lung Cancer Patients Receiving Radical Surgery and Its Association with Postoperative Venous Thromboembolism. Thoracic Cancer, 11, 1-10.</mixed-citation></ref><ref id="hanspub.37691-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Xu, K.H., et al. (2019) Establishment of a Nomogram-Based Model for Predicting the Prognostic Value of Inflammatory Biomarkers and Preoperative D-Dimer Level in Spinal Ewing's Sarcoma Family Tumors: A Retrospective Study of 83 Patients. World Neurosurgery, 121, e104-e112. &lt;br&gt;https://doi.org/10.1016/j.wneu.2018.09.022</mixed-citation></ref><ref id="hanspub.37691-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Shinohara, S., et al. (2019) Long-Term Impact of Complications after Lung Resections in Non-small Cell Lung Cancer. Journal of Thoracic Disease, 11, 2024-2033. &lt;br&gt;https://doi.org/10.21037/jtd.2019.04.91</mixed-citation></ref><ref id="hanspub.37691-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Deng, H.-Y., Zheng, X., Jiang, R., Wang, R.-L., Zhou, J. and Qiu, X.-M. (2019) Preoperative D-Dimer Level Is an Independent Prognostic Factor for Non-Small Cell Lung Cancer after Surgical Resection: A Systematic Review and Meta-Analysis. Annals of Translational Medicine, 7, 366. &lt;br&gt;https://doi.org/10.21037/atm.2019.05.35</mixed-citation></ref><ref id="hanspub.37691-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Li, R., Shao, H.-Y., Hao, L.-B., Yu, B.-Z., Qu, P.-F., Zhou,Y.-X. and Chen, J.-Y. (2019) Plasma Fibrinogen Exhibits Better Performance than Plasma D-Dimer in the Diagnosis of Periprosthetic Joint Infection: A Multicenter Retrospective Study. The Journal of Bone and Joint Surgery, 101,613-619. &lt;br&gt;https://doi.org/10.2106/JBJS.18.00624</mixed-citation></ref><ref id="hanspub.37691-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">王佳丽, 袁开芬, 张洪鹏. 血浆D-二聚体水平对非小细胞肺癌患者预后及肺栓塞发生的影响[J]. 医学研究生学报, 2016, 29(8): 849-852.</mixed-citation></ref><ref id="hanspub.37691-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">左麦红. 结直肠癌患者术前检测血浆纤维蛋白原和D-二聚体水平的临床意义[J]. 中国肛肠病杂志, 2019, 39(8): 16-17.</mixed-citation></ref><ref id="hanspub.37691-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Tekeşin, K., et al. (2016) D-Dimer and Carcinoembryonic Antigen Levels: Useful Indicators for Predicting the Tumor Stage and Postoperative Survival. Gastroenterology Research and Practice, 2016, Article ID: 4295029. 
&lt;br&gt;https://doi.org/10.1155/2016/4295029</mixed-citation></ref><ref id="hanspub.37691-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Li, h.p., et al. (2018) Combination of D-Dimer and Carcinoembryonic Antigen Levels as a Predictive and Prognostic Biomarker in Advanced Colorectal Cancer Patients. Journal of Cellular Biochemistry.</mixed-citation></ref><ref id="hanspub.37691-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">张成大, 何君, 黄婷, 等. 结直肠癌患者血清CEA和D-二聚体检测临床意义[J]. 中华肿瘤防治杂志, 2018, 25(4): 282-286.</mixed-citation></ref><ref id="hanspub.37691-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Hong, T.T., Shen, D., Chen, X.P., Wu, X.H. and Hua, D. (2017) Preoperative Plasma Fibrinogen, but Not D-Dimer Might Represent a Prognostic Factor in Non-Metastatic Colorectal Cancer: A Prospective Cohort Study. Cancer Biomarkers: Section a of Disease Markers, 19, 103-111. &lt;br&gt;https://doi.org/10.3233/CBM-160510</mixed-citation></ref></ref-list></back></article>